<div class="table-responsive">
    <table class="table table-striped table-hover">
        <thead>
            <tr>
                
                <th scope="col">
                    <a href="?cresstrial=11831&amp;modal=1&amp;valnames=arms&amp;order=created_at">Created at</a>
                </th>
                <th scope="col">Source</th>
                
                <th scope="col">Raw Value</th>
                <th scope="col">Validated value</th>
            </tr>
        </thead>
        <tbody>
            
            <tr class="histvalue-row" histvalueid="290717" class="table-">
                
                <td>Jan. 21, 2022, 2 a.m.</td>
                <td>oms</td>
                
                <td class="histvalue-container">
                    

        <p class="arms">
            [{&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Current intervention as of 10/01/2022:                Single-dose annual booster vaccination against ancestral and novel variants of SARS-CoV-2. A computer-generated randomisation list will be prepared by the study statistician. Participants in groups A and C will each be randomised 1:1:1:1 within the 2 cohorts (ChaAdOx1 nCOV-19 and BNT162b2 homologous boost); to the 4 available vaccines in each group using block randomisation. Random block sizes of 4 or 8 will be used. Participants in group B will each be randomised 1:1:1:1:1 within the 2 cohorts (ChaAdOx1 nCOV-19 and BNT162b2 homologous boost); to the 5 available vaccines in each group using block randomisation. Random block sizes of 5 or 10 will be used. The randomisation will be stratified by the study sites and age (&lt;70 and =70 years). Participants; laboratory; and analysing statisticians will remain blind to treatment allocation.                ChAdOx1-nCov19: 5x10\u00b9\u00b0 vp (0.5 ml) one IM injection                BNT162b2: 30 \u00b5g (0.3 ml) one IM injection                mRNA-1273: 0.1 mg (0.5 ml) one IM injection                NVX-CoV2373: 5 \u00b5g SARS-CoV-2 rS + 50 \u00b5g Matrix-M1 adjuvant (0.5 ml) one IM injection                NVX-CoV2373: 2.5 \u00b5g SARS-CoV-2 rS + 25 \u00b5g Matrix-M1 adjuvant (0.25 ml) one IM injection                VLA2001: 33 AU + 0.5 mg Aluminium hydroxide +1mg CPG (0.5 ml) one IM injection                VLA2001: 16.5 AU + 0.25 mg Aluminium hydroxide +0.5mg CPG (0.25 ml) one IM injection                CVnCoV : 12 \u00b5g (in 0.6 ml) one IM injection                BNT162b2: 15mcg (0.15ml) one IM injection                Janssen : 5x10\u00b9\u00b0 vp/ml (in 0.5 ml) one IM injection                MenACWY: 0.5 ml one IM injection                All participants will be followed up from 1&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}]
        </p>
    

                </td>
                <td class="histvalue-container">
                    

        <p class="arms validated">
            [{&quot;arm_notes&quot;: &quot;5x1010vp (0.5ml);1;IM;Prior ChaAdOx1 nCOV-19 or BNT162b2 homologous boost;Group A,B and C (located to different sites)&quot;, &quot;treatment_id&quot;: 161, &quot;treatment_name&quot;: &quot;Chadox1 ncov-19&quot;, &quot;treatment_type&quot;: &quot;Non replicating viral vector&quot;, &quot;pharmacological_treatment&quot;: &quot;Vaccine&quot;}, {&quot;arm_notes&quot;: &quot;5 \u00b5g SARS-CoV-2 rS + 50 \u00b5g Matrix-M1 adjuvant (0.5ml);1;IM;Prior ChaAdOx1 nCOV-19 or BNT162b2 homologous boost;Group A,B and C (located to different sites)&quot;, &quot;treatment_id&quot;: 918, &quot;treatment_name&quot;: &quot;Nvx-cov2373&quot;, &quot;treatment_type&quot;: &quot;Protein subunit&quot;, &quot;pharmacological_treatment&quot;: &quot;Vaccine&quot;}, {&quot;arm_notes&quot;: &quot;2.5 \u00b5g SARS-CoV-2 rS + 25 \u00b5g Matrix-M1 adjuvant (0.25ml);1;IM; Prior ChaAdOx1 nCOV-19 or BNT162b2 homologous boost;Group A,B and C (located to different sites)&quot;, &quot;treatment_id&quot;: 918, &quot;treatment_name&quot;: &quot;Nvx-cov2373&quot;, &quot;treatment_type&quot;: &quot;Protein subunit&quot;, &quot;pharmacological_treatment&quot;: &quot;Vaccine&quot;}, {&quot;arm_notes&quot;: &quot;30 \u00b5g (0.3ml);1;IM;Prior ChaAdOx1 nCOV-19 or BNT162b2 homologous boost;Group A,B and C (located to different sites)&quot;, &quot;treatment_id&quot;: 222, &quot;treatment_name&quot;: &quot;Bnt162b2&quot;, &quot;treatment_type&quot;: &quot;Rna based vaccine&quot;, &quot;pharmacological_treatment&quot;: &quot;Vaccine&quot;}, {&quot;arm_notes&quot;: &quot;33 AU + 0.5mg Aluminium hydroxide +1mg CPG (0.5ml);1;IM;Prior ChaAdOx1 nCOV-19 or BNT162b2 homologous boost;Group A,B and C (located to different sites)&quot;, &quot;treatment_id&quot;: 1375, &quot;treatment_name&quot;: &quot;Vla2001&quot;, &quot;treatment_type&quot;: &quot;Inactivated virus&quot;, &quot;pharmacological_treatment&quot;: &quot;Vaccine&quot;}, {&quot;arm_notes&quot;: &quot;16.5 AU + 0.25mg Aluminium hydroxide +0.5mg CPG (0.25ml);1;IM;Prior ChaAdOx1 nCOV-19 or BNT162b2 homologous boost;Group A,B and C (located to different sites)&quot;, &quot;treatment_id&quot;: 1375, &quot;treatment_name&quot;: &quot;Vla2001&quot;, &quot;treatment_type&quot;: &quot;Inactivated virus&quot;, &quot;pharmacological_treatment&quot;: &quot;Vaccine&quot;}, {&quot;arm_notes&quot;: &quot;0.1mg (0.5ml);1;IM;Prior ChaAdOx1 nCOV-19 or BNT162b2 homologous boost;Group A,B and C (located to different sites)&quot;, &quot;treatment_id&quot;: 824, &quot;treatment_name&quot;: &quot;Mrna-1273&quot;, &quot;treatment_type&quot;: &quot;Rna based vaccine&quot;, &quot;pharmacological_treatment&quot;: &quot;Vaccine&quot;}, {&quot;arm_notes&quot;: &quot;12 \u00b5g (in 0.6ml);1;IM;Prior ChaAdOx1 nCOV-19 or BNT162b2 homologous boost;Group A,B and C (located to different sites)&quot;, &quot;treatment_id&quot;: 364, &quot;treatment_name&quot;: &quot;Cvncov&quot;, &quot;treatment_type&quot;: &quot;Rna based vaccine&quot;, &quot;pharmacological_treatment&quot;: &quot;Vaccine&quot;}, {&quot;arm_notes&quot;: &quot;15 \u00b5g (0.3ml);1;IM;Prior ChaAdOx1 nCOV-19 or BNT162b2 homologous boost;Group A,B and C (located to different sites)&quot;, &quot;treatment_id&quot;: 222, &quot;treatment_name&quot;: &quot;Bnt162b2&quot;, &quot;treatment_type&quot;: &quot;Rna based vaccine&quot;, &quot;pharmacological_treatment&quot;: &quot;Vaccine&quot;}, {&quot;arm_notes&quot;: &quot;5x10\u00b9\u2070 vp/ml (in 0.5 ml);1;IM;Prior ChaAdOx1 nCOV-19 or BNT162b2 homologous boost;Group A,B and C (located to different sites)&quot;, &quot;treatment_id&quot;: 24, &quot;treatment_name&quot;: &quot;Ad26.cov2.s&quot;, &quot;treatment_type&quot;: &quot;Non replicating viral vector&quot;, &quot;pharmacological_treatment&quot;: &quot;Vaccine&quot;}, {&quot;arm_notes&quot;: &quot;0.5ml;1;IM;Prior ChaAdOx1 nCOV-19 or BNT162b2 homologous boost;Group A,B and C (located to different sites)&quot;, &quot;treatment_id&quot;: 780, &quot;treatment_name&quot;: &quot;Menacwy vaccine&quot;, &quot;treatment_type&quot;: &quot;Non covid vaccine&quot;, &quot;pharmacological_treatment&quot;: &quot;Non covid vaccine&quot;}]
        </p>
        
    
                </td>
            </tr>
            
            <tr class="histvalue-row" histvalueid="252009" class="table-">
                
                <td>June 12, 2021, 12:45 a.m.</td>
                <td>oms</td>
                
                <td class="histvalue-container">
                    

        <p class="arms">
            [{&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Current interventions as of 03/06/2021:                Single-dose annual booster vaccination against ancestral and novel variants of SARS-CoV-2. A computer-generated randomisation list will be prepared by the study statistician. Participants in groups A and C will each be randomised 1:1:1:1 within the 2 cohorts (ChaAdOx1 nCOV-19 and BNT162b2 homologous boost); to the 4 available vaccines in each group using block randomisation. Random block sizes of 4 or 8 will be used. Participants in group B will each be randomised 1:1:1:1:1 within the 2 cohorts (ChaAdOx1 nCOV-19 and BNT162b2 homologous boost); to the 5 available vaccines in each group using block randomisation. Random block sizes of 5 or 10 will be used. The randomisation will be stratified by the study sites and age (&lt;70 and =70 years). Participants; laboratory; and analysing statisticians will remain blind to treatment allocation.                ChAdOx1-nCov19: 5x10\u00b9\u00b0 vp (0.5 ml) one IM injection                BNT162b2: 30 \u00b5g (0.3 ml) one IM injection                mRNA-1273: 0.1 mg (0.5 ml) one IM injection                NVX-CoV2373: 5 \u00b5g SARS-CoV-2 rS + 50 \u00b5g Matrix-M1 adjuvant (0.5 ml) one IM injection                NVX-CoV2373: 2.5 \u00b5g SARS-CoV-2 rS + 25 \u00b5g Matrix-M1 adjuvant (0.25 ml) one IM injection                VLA2001: 33 AU + 0.5 mg Aluminium hydroxide +1mg CPG (0.5 ml) one IM injection                VLA2001: 16.5 AU + 0.25 mg Aluminium hydroxide +0.5mg CPG (0.25 ml) one IM injection                CVnCoV : 12 \u00b5g (in 0.6 ml) one IM injection                CVnCoV : 6 \u00b5g (in 0.3 ml) one IM injection                Janssen : 5x10\u00b9\u00b0 vp/ml (in 0.5 ml) one IM injection                MenACWY: 0.5 ml one IM injection                All participants will be followed up from&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}]
        </p>
    

                </td>
                <td class="histvalue-container">
                    

                </td>
            </tr>
            
            <tr class="histvalue-row" histvalueid="249101" class="table-">
                
                <td>May 20, 2021, 7:59 a.m.</td>
                <td>oms</td>
                
                <td class="histvalue-container">
                    

        <p class="arms">
            [{&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Single dose annual booster vaccination against ancestral and novel variants of SARS-CoV-2. A computer generated randomisation list will be prepared by the study statistician. Participants in groups A-C will each be randomised 1:1:1:1 within the 2 cohorts (ChaAdOx1 nCOV-19 and BNT162b2 homologous boost); to the 4 available vaccines in each group using block randomisation. Random block sizes of 4 or 8 will be used. The randomisation will be stratified by the study sites and  JCVI priority groups (1 and 2).Participants; laboratory and analysing statisticians will remain blind to treatment allocation.                ChAdOx1-nCov19: 5x1010vp (0.5ml) one IM injection                BNT162b2: 30 \u00b5g (0.3ml) one IM injection                mRNA-1273: 0.1mg (0.5ml) one IM injection                NVX-CoV2373: 5 \u00b5g SARS-CoV-2 rS + 50 \u00b5g Matrix-M1 adjuvant (0.5ml) one IM injection                NVX-CoV2373: 2.5 \u00b5g SARS-CoV-2 rS + 25 \u00b5g Matrix-M1 adjuvant (0.25ml) one IM injection                VLA2001: 33 AU + 0.5mg Aluminium hydroxide +1mg CPG (0.5ml) one IM injection                VLA2001: 16.5 AU + 0.25mg Aluminium hydroxide +0.5mg CPG (0.25ml) one IM injection                CVnCoV : 12 \u00b5g (in 0.6ml) one IM injection                CVnCoV : 6 \u00b5g (in 0.3ml) one IM injection                MenACWY: 0.5ml one IM injection                All participants will be followed up from 12 months post vaccination.&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}]
        </p>
    

                </td>
                <td class="histvalue-container">
                    

                </td>
            </tr>
            
        </tbody>
    </table>
</div>
Created at	Source	Raw Value	Validated value
Jan. 21, 2022, 2 a.m.	oms	[{"arm_notes": "", "treatment_id": null, "treatment_name": "Current intervention as of 10/01/2022: Single-dose annual booster vaccination against ancestral and novel variants of SARS-CoV-2. A computer-generated randomisation list will be prepared by the study statistician. Participants in groups A and C will each be randomised 1:1:1:1 within the 2 cohorts (ChaAdOx1 nCOV-19 and BNT162b2 homologous boost); to the 4 available vaccines in each group using block randomisation. Random block sizes of 4 or 8 will be used. Participants in group B will each be randomised 1:1:1:1:1 within the 2 cohorts (ChaAdOx1 nCOV-19 and BNT162b2 homologous boost); to the 5 available vaccines in each group using block randomisation. Random block sizes of 5 or 10 will be used. The randomisation will be stratified by the study sites and age (<70 and =70 years). Participants; laboratory; and analysing statisticians will remain blind to treatment allocation. ChAdOx1-nCov19: 5x10\u00b9\u00b0 vp (0.5 ml) one IM injection BNT162b2: 30 \u00b5g (0.3 ml) one IM injection mRNA-1273: 0.1 mg (0.5 ml) one IM injection NVX-CoV2373: 5 \u00b5g SARS-CoV-2 rS + 50 \u00b5g Matrix-M1 adjuvant (0.5 ml) one IM injection NVX-CoV2373: 2.5 \u00b5g SARS-CoV-2 rS + 25 \u00b5g Matrix-M1 adjuvant (0.25 ml) one IM injection VLA2001: 33 AU + 0.5 mg Aluminium hydroxide +1mg CPG (0.5 ml) one IM injection VLA2001: 16.5 AU + 0.25 mg Aluminium hydroxide +0.5mg CPG (0.25 ml) one IM injection CVnCoV : 12 \u00b5g (in 0.6 ml) one IM injection BNT162b2: 15mcg (0.15ml) one IM injection Janssen : 5x10\u00b9\u00b0 vp/ml (in 0.5 ml) one IM injection MenACWY: 0.5 ml one IM injection All participants will be followed up from 1", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]	[{"arm_notes": "5x1010vp (0.5ml);1;IM;Prior ChaAdOx1 nCOV-19 or BNT162b2 homologous boost;Group A,B and C (located to different sites)", "treatment_id": 161, "treatment_name": "Chadox1 ncov-19", "treatment_type": "Non replicating viral vector", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "5 \u00b5g SARS-CoV-2 rS + 50 \u00b5g Matrix-M1 adjuvant (0.5ml);1;IM;Prior ChaAdOx1 nCOV-19 or BNT162b2 homologous boost;Group A,B and C (located to different sites)", "treatment_id": 918, "treatment_name": "Nvx-cov2373", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "2.5 \u00b5g SARS-CoV-2 rS + 25 \u00b5g Matrix-M1 adjuvant (0.25ml);1;IM; Prior ChaAdOx1 nCOV-19 or BNT162b2 homologous boost;Group A,B and C (located to different sites)", "treatment_id": 918, "treatment_name": "Nvx-cov2373", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "30 \u00b5g (0.3ml);1;IM;Prior ChaAdOx1 nCOV-19 or BNT162b2 homologous boost;Group A,B and C (located to different sites)", "treatment_id": 222, "treatment_name": "Bnt162b2", "treatment_type": "Rna based vaccine", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "33 AU + 0.5mg Aluminium hydroxide +1mg CPG (0.5ml);1;IM;Prior ChaAdOx1 nCOV-19 or BNT162b2 homologous boost;Group A,B and C (located to different sites)", "treatment_id": 1375, "treatment_name": "Vla2001", "treatment_type": "Inactivated virus", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "16.5 AU + 0.25mg Aluminium hydroxide +0.5mg CPG (0.25ml);1;IM;Prior ChaAdOx1 nCOV-19 or BNT162b2 homologous boost;Group A,B and C (located to different sites)", "treatment_id": 1375, "treatment_name": "Vla2001", "treatment_type": "Inactivated virus", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "0.1mg (0.5ml);1;IM;Prior ChaAdOx1 nCOV-19 or BNT162b2 homologous boost;Group A,B and C (located to different sites)", "treatment_id": 824, "treatment_name": "Mrna-1273", "treatment_type": "Rna based vaccine", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "12 \u00b5g (in 0.6ml);1;IM;Prior ChaAdOx1 nCOV-19 or BNT162b2 homologous boost;Group A,B and C (located to different sites)", "treatment_id": 364, "treatment_name": "Cvncov", "treatment_type": "Rna based vaccine", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "15 \u00b5g (0.3ml);1;IM;Prior ChaAdOx1 nCOV-19 or BNT162b2 homologous boost;Group A,B and C (located to different sites)", "treatment_id": 222, "treatment_name": "Bnt162b2", "treatment_type": "Rna based vaccine", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "5x10\u00b9\u2070 vp/ml (in 0.5 ml);1;IM;Prior ChaAdOx1 nCOV-19 or BNT162b2 homologous boost;Group A,B and C (located to different sites)", "treatment_id": 24, "treatment_name": "Ad26.cov2.s", "treatment_type": "Non replicating viral vector", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "0.5ml;1;IM;Prior ChaAdOx1 nCOV-19 or BNT162b2 homologous boost;Group A,B and C (located to different sites)", "treatment_id": 780, "treatment_name": "Menacwy vaccine", "treatment_type": "Non covid vaccine", "pharmacological_treatment": "Non covid vaccine"}]
June 12, 2021, 12:45 a.m.	oms	[{"arm_notes": "", "treatment_id": null, "treatment_name": "Current interventions as of 03/06/2021: Single-dose annual booster vaccination against ancestral and novel variants of SARS-CoV-2. A computer-generated randomisation list will be prepared by the study statistician. Participants in groups A and C will each be randomised 1:1:1:1 within the 2 cohorts (ChaAdOx1 nCOV-19 and BNT162b2 homologous boost); to the 4 available vaccines in each group using block randomisation. Random block sizes of 4 or 8 will be used. Participants in group B will each be randomised 1:1:1:1:1 within the 2 cohorts (ChaAdOx1 nCOV-19 and BNT162b2 homologous boost); to the 5 available vaccines in each group using block randomisation. Random block sizes of 5 or 10 will be used. The randomisation will be stratified by the study sites and age (<70 and =70 years). Participants; laboratory; and analysing statisticians will remain blind to treatment allocation. ChAdOx1-nCov19: 5x10\u00b9\u00b0 vp (0.5 ml) one IM injection BNT162b2: 30 \u00b5g (0.3 ml) one IM injection mRNA-1273: 0.1 mg (0.5 ml) one IM injection NVX-CoV2373: 5 \u00b5g SARS-CoV-2 rS + 50 \u00b5g Matrix-M1 adjuvant (0.5 ml) one IM injection NVX-CoV2373: 2.5 \u00b5g SARS-CoV-2 rS + 25 \u00b5g Matrix-M1 adjuvant (0.25 ml) one IM injection VLA2001: 33 AU + 0.5 mg Aluminium hydroxide +1mg CPG (0.5 ml) one IM injection VLA2001: 16.5 AU + 0.25 mg Aluminium hydroxide +0.5mg CPG (0.25 ml) one IM injection CVnCoV : 12 \u00b5g (in 0.6 ml) one IM injection CVnCoV : 6 \u00b5g (in 0.3 ml) one IM injection Janssen : 5x10\u00b9\u00b0 vp/ml (in 0.5 ml) one IM injection MenACWY: 0.5 ml one IM injection All participants will be followed up from", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]
May 20, 2021, 7:59 a.m.	oms	[{"arm_notes": "", "treatment_id": null, "treatment_name": "Single dose annual booster vaccination against ancestral and novel variants of SARS-CoV-2. A computer generated randomisation list will be prepared by the study statistician. Participants in groups A-C will each be randomised 1:1:1:1 within the 2 cohorts (ChaAdOx1 nCOV-19 and BNT162b2 homologous boost); to the 4 available vaccines in each group using block randomisation. Random block sizes of 4 or 8 will be used. The randomisation will be stratified by the study sites and JCVI priority groups (1 and 2).Participants; laboratory and analysing statisticians will remain blind to treatment allocation. ChAdOx1-nCov19: 5x1010vp (0.5ml) one IM injection BNT162b2: 30 \u00b5g (0.3ml) one IM injection mRNA-1273: 0.1mg (0.5ml) one IM injection NVX-CoV2373: 5 \u00b5g SARS-CoV-2 rS + 50 \u00b5g Matrix-M1 adjuvant (0.5ml) one IM injection NVX-CoV2373: 2.5 \u00b5g SARS-CoV-2 rS + 25 \u00b5g Matrix-M1 adjuvant (0.25ml) one IM injection VLA2001: 33 AU + 0.5mg Aluminium hydroxide +1mg CPG (0.5ml) one IM injection VLA2001: 16.5 AU + 0.25mg Aluminium hydroxide +0.5mg CPG (0.25ml) one IM injection CVnCoV : 12 \u00b5g (in 0.6ml) one IM injection CVnCoV : 6 \u00b5g (in 0.3ml) one IM injection MenACWY: 0.5ml one IM injection All participants will be followed up from 12 months post vaccination.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]